Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Medtronic PLC — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.09 (market cap $44.49B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 2.5× JPMorgan Nasdaq Equity Premium Income ETF's market cap, and Medtronic PLC pays a 3.28% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and Medtronic PLC for 63 Days on average.
| JEPQ | MDT | |
|---|---|---|
Market Cap | $44.49B | $112.24B |
Volume | 5,681,789 | 105,663,236 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $105.35 |
52-Week Low | $53.77 | $73.75 |
Typical Hold Time | 66 Days | 63 Days |
Enterprise Value | — | $131.58B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.93, down 0.55% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's covered-call strategy generates substantial monthly income, with recent dividends ranging from $0.57 to $0.70 per share. Recent news highlights JEPQ's 11% estimated annual yield and its positioning in AI-driven tech stocks, though the strategy limits upside potential during strong market rallies.
JEPQ offers high income generation through its Nasdaq-focused covered-call approach, making it attractive for retirees seeking monthly cash flow. However, the strategy caps appreciation potential and faces volatility sensitivity, requiring proper portfolio sizing. Key risks include market volatility dependence and competitive pressure from similar income ETFs with different tax treatments.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 49-year dividend growth streak. The stock shows bearish technical signals but maintains solid profitability with 13.93% net margins and positive cash flow trends. Recent regulatory approvals for medical devices and raised guidance signal operational momentum despite mixed technical indicators.
Outlook remains positive with analyst consensus at $97.80 (11% upside) and no sell ratings, though technical weakness and increasing debt-to-asset ratios pose near-term risks. The 3.2% dividend yield provides income support while revenue growth acceleration to $37.5B projected for 2026 offers growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
